首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1919952

溶瘤病毒療法市場規模、佔有率及成長分析（按病毒類型、癌症類型、治療方法、給藥途徑、最終用戶和地區分類）－2026-2033年產業預測

Oncolytic Virus Therapy Market Size, Share, and Growth Analysis, By Virus Type (Adenovirus, Herpes Simplex Virus), By Cancer Type, By Therapy Type, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月09日 | 出版商:

SkyQuest | 英文 184 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球溶瘤病毒療法市場規模預計在 2024 年達到 4.114 億美元，從 2025 年的 5.1713 億美元成長到 2033 年的 32.2316 億美元，在預測期（2026-2033 年）內複合年成長率為 25.7%。

市場分析表明，由於癌症病例的不斷增加以及人們對溶瘤病毒治療效果日益成長的興趣，溶瘤病毒療法行業預計將迎來顯著成長。創新影像技術的進步，以及持續的研發投入，進一步提升了此治療方法的吸引力。此外，科學突破與臨床應用的整合有望推動該領域的投資和創新。醫療保健和生物技術行業的相關人員認知到溶瘤病毒療法具有顛覆性的巨大潛力，這為市場的強勁擴張和腫瘤學新治療方法的湧現提供了廣闊前景。這種不斷變化的市場格局預示著癌症治療方法的變革性轉變。

全球溶瘤病毒療法市場促進因素

全球癌症發生率的不斷上升，使得人們迫切需要更具針對性和更有效的治療方法，溶瘤病毒療法的需求也因此顯著成長。傳統的治療方法，例如化療和放療，由於其局限性，往往效果不佳，促使患者和醫護人員尋求其他解決方案。溶瘤病毒療法提供了一種全新的方法，它能夠特異性攻擊癌細胞，同時刺激免疫系統。這種雙重作用不僅有助於摧毀癌細胞，還能增強人體對病毒和癌症的免疫反應，使其成為極具前景的治療方法。

限制全球溶瘤病毒療法市場的因素

溶瘤病毒療法市場受到許多因素的限制，這些因素導致其高成本，包括複雜的基因工程流程、繁複的生產技術以及生產後必須立即處理的材料的嚴格儲存要求。因此，這些經濟障礙使得許多低收入患者無法負擔治療費用，限制了他們在注重成本的醫療保健系統中從這種創新治療方法中獲益的機會。這造成了治療機會的不均等，並限制了溶瘤病毒療法在不同人群中癌症治療的潛在影響。

全球溶瘤病毒療法市場趨勢

基因工程的突破使得精準標靶化癌細胞並保護健康組織成為可能，顯著推動了全球溶瘤病毒療法市場的成長。研究人員正持續開發病毒改造技術，這些技術不僅能直接攻擊腫瘤，還能透過整合細胞激素和查核點抑制劑來增強身體的免疫反應。先進技術的進步為溶瘤療法帶來了創新方法，為更有效的治療方法鋪平了道路，這些方案可在臨床環境中即時調整。這一趨勢反映了腫瘤學領域向個人化醫療的更廣泛轉變，並將溶瘤病毒療法定位為癌症治療領域一個充滿希望的新前沿。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Amgen
SillaJen
PsiOxus Therapeutics
Transgene
Oncolytics Biotech
Replimune Group
Viralytics
Virotherapy Center
DNAtrix
Genelux
Turnstone Biologics
Vyriad
Oncorus
Lokon Pharma
Sorrento Therapeutics
BioVex
CG Oncology
ImmVirX
Hookipa Pharma
Theriva Biologics

結論與建議

簡介目錄

Product Code: SQMIG35H2403

Global Oncolytic Virus Therapy Market size was valued at USD 411.4 million in 2024 and is poised to grow from USD 517.13 million in 2025 to USD 3223.16 million by 2033, growing at a CAGR of 25.7% during the forecast period (2026-2033).

Market insights indicate that the oncolytic virus therapy industry is poised for significant growth due to an increasing prevalence of cancer cases and heightened interest in the therapeutic benefits of oncolytic viruses. The advancement of innovative imaging technologies, coupled with ongoing research and development efforts, is further enhancing the appeal of this treatment modality. Additionally, the convergence of scientific breakthroughs and clinical applications will likely drive investment and innovation within the sector. Stakeholders in the healthcare and biotechnology industries are recognizing the potential of oncolytic virus therapy as a game-changing approach, positioning the market for robust expansion and promising opportunities for novel therapeutics in oncology. This evolving landscape signals a transformative shift in cancer treatment methodologies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncolytic Virus Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncolytic Virus Therapy Market Segments Analysis

Global Oncolytic Virus Therapy Market is segmented by Virus Type, Cancer Type, Therapy Type, Route of Administration, End User and region. Based on Virus Type, the market is segmented into Adenovirus, Herpes Simplex Virus, Reovirus, Vaccinia Virus and Others. Based on Cancer Type, the market is segmented into Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer and Others. Based on Therapy Type, the market is segmented into Monotherapy and Combination Therapy. Based on Route of Administration, the market is segmented into Intratumoral and Intravenous. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Oncolytic Virus Therapy Market

The rising incidence of cancers globally is driving a substantial demand for oncolytic virus therapies, as there is a pressing need for more targeted and effective treatment options. Traditional treatment methods, like chemotherapy and radiation, often fall short due to their limitations, prompting patients and healthcare providers to look for alternative solutions. Oncolytic virus therapies offer a novel approach by specifically attacking cancer cells while simultaneously stimulating the immune system. This dual action not only helps in destroying the cancerous cells but also enhances the body's immune response against both the virus and the cancer, making it a promising therapeutic avenue.

Restraints in the Global Oncolytic Virus Therapy Market

The oncolytic virus therapy market is hindered by numerous factors leading to its elevated costs. These include the sophisticated processes involved in genetic engineering, intricate manufacturing techniques, and the strict storage requirements for the materials, which must be addressed immediately after production. Consequently, these financial obstacles restrict access for many patients in lower-income communities and curtail opportunities for individuals within cost-sensitive healthcare systems to benefit from this innovative treatment option. This situation creates a disparity in accessibility, limiting the potential impact of oncolytic virus therapies in addressing cancer across diverse populations.

Market Trends of the Global Oncolytic Virus Therapy Market

The Global Oncolytic Virus Therapy market is experiencing significant growth driven by breakthroughs in genetic engineering, which enable precise targeting of cancer cells while sparing healthy tissue. Researchers are increasingly able to modify viruses to not only attack tumors directly but also enhance the body's immune response through the incorporation of cytokines and checkpoint inhibitors. As advanced technologies evolve, they facilitate innovative approaches to oncolytic therapies, paving the way for more effective treatments that can be tailored in real-time within clinical settings. This trend reflects a broader shift towards personalized medicine in oncology, positioning oncolytic virus therapy as a promising frontier in cancer treatment.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment
Technology Assessment
Regulatory Landscape

Global Oncolytic Virus Therapy Market Size by Virus Type & CAGR (2026-2033)

Market Overview
Adenovirus
Herpes Simplex Virus
Reovirus
Vaccinia Virus
Others

Global Oncolytic Virus Therapy Market Size by Cancer Type & CAGR (2026-2033)

Market Overview
Melanoma
Lung Cancer
Breast Cancer
Colorectal Cancer
Others

Global Oncolytic Virus Therapy Market Size by Therapy Type & CAGR (2026-2033)

Market Overview
Monotherapy
Combination Therapy

Global Oncolytic Virus Therapy Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Intratumoral
Intravenous

Global Oncolytic Virus Therapy Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Research Institutes

Global Oncolytic Virus Therapy Market Size & CAGR (2026-2033)

North America (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- US
- Canada
Europe (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Virus Type, Cancer Type, Therapy Type, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SillaJen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PsiOxus Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Transgene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncolytics Biotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Replimune Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viralytics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virotherapy Center
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
DNAtrix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genelux
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Turnstone Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vyriad
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncorus
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lokon Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sorrento Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioVex
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CG Oncology
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmVirX
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hookipa Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Theriva Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments